natgillin/translations-raw huggingface dataset:
In these studies the dose of efavirenz was 600 mg once daily; the dose of indinavir was 1,000 mg every 8 hours when used with efavirenz and 800 mg every 8 hours when used without efavirenz. 
U tim je studijama efavirenz primjenjivan u dozi od 600 mg jedanput na dan; doza indinavira bila je 1000 mg svakih 8 sati kad se primjenjivao u kombinaciji s efavirenzom, odnosno 800 mg svakih 8 sati kad se primjenjivao bez efavirenza.
Sufficient data on the tolerability of efavirenz with low-dose ritonavir (100 mg, once or twice daily) are not available. 
Nema dovoljno podataka o podnošljivosti efavirenza s niskom dozom ritonavira (100 mg jedanput ili dvaput na dan).
Efavirenz has also been shown to induce UGT1A1. 
Efavirenz također inducira UGT1A1.
- Sertraline (a medicine used to treat depression): your doctor may need to change your dose of sertraline. 
- Sertralin (lijek za liječenje depresije): liječnik će Vam možda trebati promijeniti dozu sertralina.
In a 3-month drug interaction study, no significant differences in MPA pharmacokinetic parameters were found between subjects receiving efavirenz-containing antiretroviral therapy and subjects receiving no antiretroviral therapy. 
U tromjesečnom ispitivanju interakcija lijekova nisu ustanovljene značajne razlike u farmakokinetičkim parametrima MPA između ispitanika koji su primali antiretrovirusnu terapiju koja je sadržavala efavirenz i ispitanika koji nisu primali antiretrovirusnu terapiju.
Taking these medicines with Efavirenz Teva could create the potential for serious and/or life-threatening side effects or stop Efavirenz Teva from working properly. 
Uzimanje ovih lijekova s Efavirenzom Teva može dovesti do razvoja ozbiljnih i/ili po život opasnih nuspojava ili spriječiti ispravno djelovanje Efavirenza Teva.
Although cross-resistance of efavirenz with PIs has not been documented, there are at present insufficient data on the efficacy of subsequent use of PI-based combination therapy after failure of regimens containing efavirenz. 
Iako nije dokazana ukrižena rezistencija efavirenza s inhibitorima proteaze, zasad nema dovoljno podataka o djelotvornosti naknadne primjene kombinirane terapije inhibitorima proteaze nakon neuspjeha terapije koja je sadržavala efavirenz.
Reported rates of recurrent rash following a switch from nevirapine to efavirenz therapy, primarily based on retrospective cohort data from published literature, range from 13 to 18%, comparable to the rate observed in patients treated with efavirenz in clinical studies (see section 4.4). 
Opažene stope rekurentnog osipa nakon prelaska s liječenja nevirapinom na liječenje efavirenzom, na temelju podataka iz retrospektivnih kohortnih ispitivanja iz objavljene literature, kreću se od 13 do 18%, što je usporedivo sa stopama opaženim u bolesnika liječenih efavirenzom u kliničkim ispitivanjima (vidjeti dio 4.4).).
A multiple-dose study showed no significant effect on efavirenz pharmacokinetics in patients with mild hepatic impairment (Child-Pugh Class A) compared with controls. 
Ispitivanje s višekratnim dozama nije pokazalo značajan učinak na farmakokinetiku efavirenza u bolesnika s blagim oštećenjem jetre (Child-Pugh stadij A) u odnosu na kontrolnu skupinu.
Two of three delavirdine-resistant clinical isolates examined were cross-resistant to efavirenz and contained the K103N substitution. 
Dva od tri ispitana klinička izolata rezistentna na delavirdin bila su križno rezistentna na efavirenz i imala su zamjenu K103N.
Phenytoin, phenobarbital, and other anticonvulsants that are substrates of CYP450 isoenzymes 
Fenitoin, fenobarbital i drugi antikonvulzivi koji su supstrati izoenzima CYP450
White opaque PVC/PVdC-aluminium or aluminium-aluminium blisters in a carton containing 30 or 90 film-coated tablets. 
Bijeli, neprozirni, PVC/PVdC-aluminijski ili aluminij-aluminijski blisteri u kutiji sa 30 ili 90 filmom obloženih tableta.
Efavirenz has been shown to induce CYP3A4 and CYP2B6, resulting in the induction of its own metabolism which may be clinically relevant in some patients. 
Pokazalo se da efavirenz inducira CYP3A4 i CYP2B6, što dovodi do indukcije njegovog vlastitog metabolizma i može biti klinički značajno u nekih bolesnika.
Recommendation concerning co-administration with efavirenz once daily) 
Preporuke vezano za istodobnu primjenu s efavirenzom jedanput na dan)
There is a potential for reduction or increase in the plasma concentrations of phenytoin, phenobarbital and other anticonvulsants that are substrates of CYP450 isoenzymes when co-administered with efavirenz. 
Postoji mogućnost sniženja ili povišenja plazmatske koncentracije fenitoina, fenobarbitala i drugih antikonvulziva koji su supstrati izoenzima CYP450 kad se primjenjuju istodobno s efavirenzom.
If you forget to take Efavirenz Teva 
Ako ste zaboravili uzeti Efavirenz Teva
Two controlled studies (006 and ACTG 364) of approximately one-year duration with efavirenz in combination with NRTIs and/or PIs, have demonstrated reduction of viral load below the limit of quantification of the assay and increased CD4 lymphocytes in antiretroviral therapy-naïve and NRTI-experienced HIV infected patients. 
Dvije kontrolirane studije (006 i ACTG 364) u trajanju od oko godinu dana u kojima je efavirenz primjenjivan u kombinaciji s NRTI-jima i/ili inhibitorima proteaze pokazale su smanjenje virusnoga opterećenja ispod granice određivanja laboratorijskog testa, te porast CD4 limfocita u bolesnika zaraženih HIV virusom bez prethodnog antiretrovirusnog liječenja kao i u onih koji su primali NRTI
Patients should be monitored carefully for dose-related adverse reactions, especially nervous system symptoms. 
Takve bolesnike treba pomno nadzirati zbog pojave nuspojava ovisnih o dozi, posebno simptoma sa strane živčanog sustava.
Table 3: Efficacy results for studies ACTG 364 and 020 Responder rates (NC = Fa) Plasma HIV-RNA 
Tablica 3: Rezultati djelotvornosti iz ispitivanja ACTG 364 i 020 Stope bolesnika s odgovorom (NC = Fa) HIV-RNK u plazmi
Efavirenz must be given in combination with other antiretroviral medicines (see section 4.5). 
Doziranje Efavirenz se mora primjenjivati u kombinaciji s drugim antiretrovirusnim lijekovima (vidjeti dio 4.5).
IMMUNOSUPPRESSANTS Immunosuppressants metabolized by CYP3A4 (e.g. cyclosporine, tacrolimus, sirolimus)/efavirenz 
Imunosupresivi koji se metaboliziraju putem CYP3A4 (npr. ciklosporin, takrolimus, sirolimus)/efavirenz
PARTICULARS TO APPEAR ON THE OUTER PACKAGING CARTON FOR BLISTER PACK CONTAINING OF <30><30x1><90><90 x 1> EFAVIRENZ TEVA 600 mg FILM-COATED TABLETS 
PODACI KOJI SE MORAJU NALAZITI NA VANJSKOM PAKIRANJU KUTIJA ZA PAKIRANJE S BLISTEROM SADRŽI <30><30x1><90><90 x 1> EFAVIRENZ TEVA 600 mg FILMOM OBLOŽENIH
Because of the extensive cytochrome P450-mediated metabolism of efavirenz and limited clinical experience in patients with chronic liver disease, caution must be exercised in administering efavirenz to patients with mild hepatic impairment. 
Zbog značajnog metaboliziranja efavirenza posredstvom citokroma P-450 i zbog ograničenih kliničkih iskustava u bolesnika s kroničnom bolesti jetre, treba biti oprezan u primjeni efavirenza u bolesnika s blagom do umjerenom bolesti jetre.
The film-coating agent contains hypromellose, lactose monohydrate, titanium dioxide, macrogol/PEG 3350, triacetin and iron oxide yellow. 
Sastojak film ovojnice sadrži hipromelozu, laktozu hidrat, titanijev dioksid, makrogol/PEG 3350, triacetin i žuti željezov oksid.
Time to peak plasma concentrations (3-5 hours) did not change following multiple dosing and steady-state plasma concentrations were reached in 67 days. 
Vrijeme potrebno za postizanje vršne koncentracije (3-5 sati), nije se mijenjalo kod višekratnog doziranja, a koncentracije u stanju dinamičke ravnoteže postizale su se nakon 6-7 dana.
In in vitro studies efavirenz did not inhibit CYP2E1 and inhibited CYP2D6 and CYP1A2 only at concentrations well above those achieved clinically. 
U istraživanjima in vitro efavirenz nije inhibirao CYP2E1, a CYP2D6 i CYP1A2 je inhibirao samo pri koncentracijama koje su bile znatno više od onih u kliničkoj primjeni.
Experience with efavirenz in patients who discontinued other antiretroviral agents of the NNRTI class is limited (see section 4.8). 
Iskustvo s primjenom efavirenza u bolesnika koji su prekinuli terapiju drugim antiretrovirusnim lijekovima iz klase NNRTI-a je ograničeno (vidjeti dio 4.8).
The effect of efavirenz on male and female fertility in rats has only been evaluated at doses that achieved systemic drug exposures equivalent to or below those achieved in humans given recommended doses of efavirenz. 
Učinak efavirenza na plodnost mužjaka i ženki štakora ispitivan je samo pri dozama kojima se postiže sistemska izloženost lijeku jednaka ili manja sistemskoj izloženosti u ljudi koji su primali preporučene doze efavirenza.
The mechanism of tumour formation and the potential relevance for humans are not known. 
Nije poznat mehanizam nastajanja tumora, kao ni mogući značaj u ljudi.
2-hydroxy atorvastatin: 
2-hidroksi atorvastatin:
The long-term safety profile of efavirenz-containing regimens was evaluated in a controlled trial (006) in which patients received efavirenz + zidovudine + lamivudine (n = 412, median duration 180 weeks), efavirenz + indinavir (n = 415, median duration 102 weeks), or indinavir + zidovudine + lamivudine (n = 401, median duration 76 weeks). 
Dugoročan sigurnosni profil protokola s efavirenzom ispitan je u kontroliranom ispitivanju (006) u kojemu su bolesnici primali efavirenz + zidovudin + lamivudin (n=412, medijan trajanja 180 tjedana), efavirenz + indinavir (n=415, medijan trajanja 102 tjedna) ili indinavir + zidovudin + lamivudin (n=401, medijan trajanja 76 tjedana).
A few of the postmarketing reports of hepatic failure, including cases in patients with no pre-existing hepatic disease or other identifiable risk factors, were characterized by a fulminant course, progressing in some cases to transplantation or death. 
U nekoliko prijavljenih slučajeva, nakon stavljanja lijeka u promet, uključujući i one bez prethodne bolesti jetre ili drugih prepoznatljivih čimbenika rizika, opisan je fulminantni tijek, koji je u nekim slučajevima napredovao do transplantacije ili smrti.
Cmin: ↓ 12% (↓ 24% to ↑ 1%) 
Cmin: ↓ 12% (↓ 24% do ↑ 1%)
- Medicines used to treat fungal infections (antifungals): 
- Lijekove za liječenje gljivičnih infekcija (antimikotike):
Do not take Efavirenz Teva). 
Ne uzimajte Efavirenz Teva).
‡These adverse reactions were identified through post-marketing surveillance but not reported as drug-related events for efavirenz-treated patients in 16 clinical trials. 
‡ Ove nuspojave zabilježene su tijekom praćenja nakon stavljanja lijeka u promet, ali nisu prijavljene kao nuspojave povezane s lijekom u bolesnika liječenih efavirenzom u 16 kliničkih ispitivanja.
Study 020 showed similar activity in NRTI-experienced patients over 24 weeks. 
Studija 020 pokazala je sličan učinak tijekom 24-tjedne primjene u bolesnika koji su već primali
In a study of uninfected volunteers, a representative nervous system symptom had a median time to onset of 1 hour post-dose and a median duration of 3 hours. 
U ispitivanju nezaraženih dobrovoljaca tipični simptomi živčanog sustava javljali su se s medijanom vremena pojave od 1 sat nakon uzimanja lijeka, te s medijanom trajanja od
Non-sustained convulsions were observed in some monkeys receiving efavirenz for ≥ 1 year, at doses yielding plasma AUC values 4- to 13-fold greater than those in humans given the recommended dose (see sections 4.4 and 4.8). 
Nepostojane konvulzije zapažene su kod nekih majmuna koji su efavirenz primali ≥1 godine u dozama kojima su postignute vrijednosti AUC 4 do 13 puta veće od onih u ljudi koji su primali preporučenu dozu lijeka (vidjeti dijelove 4.4 i 4.8).
In HIV infected patients with severe immune deficiency at the time of initiation of combination antiretroviral therapy (CART), an inflammatory reaction to asymptomatic or residual opportunistic infections may arise. 
U pacijenata inficiranih HIV-om s teškom imunodeficijencijom u vrijeme početka kombinirane antiretrovirusne terapije (CART) može nastati upalna reakcija na asimptomatske ili rezidualne oportunističke infekcije.
The potential for cross-resistance between efavirenz and PIs is low because of the different enzyme targets involved. 
Potencijal za križnu rezistenciju između efavirenza i inhibitora proteaze je nizak, zbog vezanja na različite ciljne enzime.
(CYP3A4 induction) Co-administration of efavirenz with atorvastatin, pravastatin, or simvastatin did not affect efavirenz AUC or Cmax values. 
(indukcija CYP3A4) Istodobna primjena efavirenza s atorvastatinom, pravastatinom ili simvastatinom nije utjecala na vrijednosti AUC ni Cmax efavirenza
The dose of lopinavir/ritonavir tablets should be increased to 500/125 mg twice daily when co-administered with efavirenz 600 mg once daily. 
Dozu lopinavir/ritonavir tableta treba povisiti na 500/125 mg dvaput na dan kada se primjenjuju istodobno s efavirenzom u dozi od 600 mg jedanput na dan.
In clinical studies 2% of patients treated with efavirenz discontinued therapy due to such symptoms. 
2% bolesnika liječenih efavirenzom prekinulo terapiju zbog ovih simptoma.
Because of the limited information available, a reliable method of barrier contraception must be used in addition to hormonal contraceptives (see section 4.6). 
Zbog ograničenosti dostupnih podataka, uz hormonske kontraceptive treba koristiti i pouzdanu mehaničku metodu kontracepcije (vidjeti dio 4.6).
Efavirenz: no clinically significant interaction. 
Efavirenz: nema klinički značajnih interakcija.
Multipack: 90 (3 packs of 30 x 1) film-coated tablets 
Višestruko pakiranje: 90 (3 pakiranja sa 30 x 1) filmom obloženih tableta
Barrier contraception should always be used in combination with other methods of contraception (for example, oral or other hormonal contraceptives, see section 4.5). 
Uvijek treba primjenjivati mehanička kontracepcijska sredstva u kombinaciji s drugim metodama kontracepcije (kao što su peroralni i drugi hormonski kontraceptivi, vidjeti dio 4.5).
In some patients with advanced HIV infection (AIDS) and a history of opportunistic infection, signs and symptoms of inflammation from previous infections may occur soon after anti-HIV treatment is started. 
infekcijom (AIDS), koji su već imali oportunističke infekcije, znakovi i simptomi upale od prijašnjih infekcija mogu nastupiti ubrzo nakon početka anti-HIV liječenja.
Nervous system symptoms of moderate-to-severe intensity were experienced by 19% (severe 2%) of patients compared to 9% (severe 1%) of patients receiving control regimens. 
Simptomi živčanog sustava umjerenog do jakog intenziteta zabilježeni su u 19% bolesnika (teški u 2%) koji su primali efavirenz, u odnosu na 9% bolesnika u kontrolnoj skupini (teški u 1%).
< 400 copies/ml (95% C.I.b) 
< 400 kopija/ml (95% C.I.b)
The antiretroviral medicinal products should be restarted at the same time upon resolution of the intolerance symptoms. 
Također, antiretrovirusne lijekove treba ponovo uvesti u kombiniranu terapiju istodobno s povlačenjem simptoma nepodnošenja lijeka.
Forty-three patients 3 months to 21 years of age (median 9.6 years) were dosed with efavirenz. 
Četrdeset tri bolesnika u dobi od 3 mjeseca do 21 godinu (medijan 9,6 godina) primali su efavirenz.
Posaconazole: 
Posakonazol:
When treatment with voriconazole is stopped, the initial dosage of efavirenz should be restored. 
Kada liječenje vorikonazolom završi, mora se ponovno dati početna doza efavirenza.
The in vitro studies suggest that CYP3A4 and CYP2B6 are the major isozymes responsible for efavirenz metabolism and that it inhibited P450 isozymes 2C9, 2C19, and 3A4. 
Istraživanja in vitro ukazuju da su CYP3A4 i CYP2B6 glavni izoenzimi uključeni u metabolizam efavirenza te da efavirenz inhibira P450 izoenzime 2C9, 2C19 i 3A4.
Protease inhibitor : Elbasvir/grazoprevir 
Inhibitor proteaze: elbasvir/grazoprevir
One hundred two patients 3 months to 16 years of age (median 5.7 years) were treated with efavirenz. 
Stotinu i dva bolesnika u dobi od 3 mjeseca do 16 godina (medijan 5,7 godina) liječeni su efavirenzom.
- itchy rash caused by a reaction to sunlight - liver failure, in some cases leading to death or liver transplant, has occurred with efavirenz. 
- osip koji svrbi uzrokovan reakcijom na Sunčevu svjetlost - kod primjene efavirenza nastupilo je zatajenje jetre, koje je u nekim slučajevima dovelo do smrti ili presađivanja jetre.
Appropriate antihistamines and/or corticosteroids may improve the tolerability and hasten the resolution of rash. 
Primjena odgovarajućih antihistaminika i/ili kortikosteroida može poboljšati podnošenje lijeka i ubrzati nestajanje osipa.
Efavirenz Teva film-coated tablets are not recommended for children under the age of 3 years or weighing less than 40 kg. 
Efavirenz Teva filmom obložene tablete se ne preporučuju za djecu mlađu od 3 godine ili djecu tjelesne težine manje od 40 kg.
Pliva Hrvatska d.o.o. 
PLIVA Hrvatska d.o.o. (PLIVA Croatia Ltd.)
NNRTIs/efavirenz 
NNRTI/efavirenz
Pharmacotherapeutic group: Antivirals for systemic use, non-nucleoside reverse transcriptase inhibitors. 
Farmakoterapijska skupina: Antivirusni lijekovi za sistemsku primjenu; nenukleozidni inhibitori reverzne transkriptaze.
They include some common medicines and a herbal remedy (St. John's wort) which can cause serious interactions. 
Obuhvaćaju neke često primjenjivane lijekove i biljni pripravak (gospinu travu) koji mogu izazvati ozbiljne interakcije.
protease inhibitors: darunavir, indinavir, lopinavir/ritonavir, ritonavir, ritonavir-boosted atazanavir, saquinavir or fosamprenavir/saquinavir. 
inhibitore proteaze: darunavir, indinavir, lopinavir/ritonavir, ritonavir, ritonavirom pojačan atazanavir, sakvinavir ili fosamprenavir/sakvinavir.
Similar results were found by other investigators, although the MPA plasma levels were more variable in the second study. 
Slične su rezultate dobili i drugi ispitivači, premda su razine MPA
Studies in humans and in vitro studies using human liver microsomes have demonstrated that efavirenz is principally metabolised by the cytochrome P450 system to hydroxylated metabolites with subsequent glucuronidation of these hydroxylated metabolites. 
Ispitivanja u ljudi i istraživanja in vitro na humanim jetrenim mikrosomima pokazala su da se efavirenz najvećim dijelom razgrađuje posredstvom sustava citokroma P450 do hidroksiliranih metabolita, nakon čega slijedi njihova glukuronidacija.
(CYP3A4 induction) * When compared to atazanavir 300 mg/ritonavir 100 mg once daily in the evening without efavirenz. 
(indukcija CYP3A4) * u usporedbi s kombinacijom atazanavir 300 mg/ritonavir 100 mg jedanput na dan navečer, bez efavirenza.
Neither aluminium/magnesium hydroxide antacids nor famotidine altered the absorption of efavirenz. 
Antacidi koji sadrže aluminijev/magnezijev hidroksid kao niti famotidin nisu mijenjali apsorpciju efavirenza.
<50 copies/ml (95% C.I.b) 
<50 kopija /ml (95% C.I.b)
In a subset of 1,008 adult patients who received 600 mg efavirenz daily in combination with PIs and/or NRTIs in controlled clinical studies, the most frequently reported adverse reactions of at least moderate severity reported in at least 5% of patients were rash (11.6%), dizziness (8.5%), nausea (8.0%), headache (5.7%) and fatigue (5.5%). 
U podskupini od 1008 odraslih bolesnika koji su u kontroliranim kliničkim ispitivanjima primali efavirenz u dozi od 600 mg na dan u kombinaciji s inhibitorima proteaze i/ili NRTI-ma najčešće nuspojave koje su bile najmanje umjerene težine i prijavljene u najmanje 5% bolesnika bile su: osip (11,6%), omaglica (8,5%), mučnina (8,0%),
See package leaflet for further information. 
Opis odabranih nuspojava za detaljnije informacije.
If the co-administration of atazanavir with an NNRTI is required, an increase in the dose of both atazanavir and ritonavir to 400 mg and 200 mg, respectively, in combination with efavirenz could be considered with close clinical monitoring. 
Ako je potrebno primjenjivati atazanavir istodobno s NNRTI-jem, može se razmotriti povišenje doze atazanavira na 400 mg i ritonavira na 200 mg, u kombinaciji s efavirenzom, pod pomnim kliničkim nadzorom.
It is recommended that efavirenz be taken on an empty stomach. 
Preporučuje se efavirenz uzimati na prazan želudac.
Norbuprenorphine: 
Norbuprenorfin:
No dose adjustment is necessary 
Nije potrebno prilagođavati dozu
- skin rash 
- kožni osip
No effect (↔) equals a decrease in mean ratio estimate of ≤20% or increase in mean ratio estimate of administered with efavirenz. 
Nema utjecaja (↔) jednako smanjenje procjene srednje vrijednosti omjera od ≤20% ili povećanje procjene srednje vrijednosti omjera od ≤25%
Thirty-seven patients 3 months to 6 years of age (median 0.7 years) were treated with efavirenz. 
Trideset sedmero bolesnika u dobi od 3 mjeseca do 6 godina (medijan 0,7 godina) liječeno je efavirenzom.
These drugs include: - antiarrhythmics of classes IA and III, - neuroleptics, antidepressive agents, 
antiartimike skupina IA i III, neuroleptike, antidepresive,
Patients with: - a family history of sudden death or of congenital prolongation of the QTc interval on electrocardiograms, or with any other clinical condition known to prolong the QTc interval. 
iznenadnu smrt ili kongenitalno produljenje QTc intervala na elektrokardiogramu u obiteljskoj anamnezi, ili bilo koje drugo kliničko stanje za koje je poznato da uzrokuje produljenje QTc intervala.
Uncommon Erythema multiforme, Stevens-Johnson syndrome* Rare 
često pruritus manje često Erythema multiforme, Stevens-Johnsonov sindrom* rijetko fotoalergijski dermatitis†
A similar reduction in indinavir exposures was observed when indinavir 1000 mg q8h was given with efavirenz 600 mg daily. 
Slično smanjenje izloženosti indinaviru opaženo je kad se indinavir 1000 mg q8h primjenjivao s efavirenzom 600 mg na dan. (indukcija CYP3A4)
if you have a history of convulsions (fits or seizures) or if you are being treated with anticonvulsant therapy such as carbamazepine, phenobarbital and phenytoin. 
o ako ste imali konvulzije (napadaje) ili se liječite antikonvulzivnim lijekovima kao što su karbamazepin, fenobarbital i fenitoin.
Biliary hyperplasia was observed in cynomolgus monkeys given efavirenz for ≥ 1 year at a dose resulting in mean AUC values approximately 2-fold greater than those in humans given the recommended dose. 
Bilijarna hiperplazija opažena je kod cinomolgus majmuna koji su efavirenz primali ≥1 godine u dozama koje su postizale srednje vrijednosti AUC gotovo dvosruko veće od onih postignutih u ljudi, pri preporučenim dozama lijeka.
Individual tolerability and virological response should be considered when making the dose adjustment (see section 5.2). 
Pri prilagođavanju doze potrebno je uzeti u obzir individualnu podnošljivost i virološki odgovor (vidjeti dio 5.2).
When prescribing medicinal products concomitantly with efavirenz, physicians should refer to the corresponding Summary of Product Characteristics. 
Pri propisivanju lijekova koji se primjenjuju istodobno s efavirenzom, liječnici trebaju proučiti sažetak opisa svojstava lijeka za te lijekove.
4-hydroxy atorvastatin: 
4-hidroksi atorvastatin:
Because of the long half-life of efavirenz, use of adequate contraceptive measures for 12 weeks after discontinuation of efavirenz is recommended. 
Zbog dugog poluvijeka efavirenza, preporučuje se primjena odgovarajućih kontracepcijskih metoda tijekom 12
Artemether: 
Artemeter:
When taken with rifampicin in patients weighing 50 kg or greater, increasing efavirenz daily dose to 800 mg may provide exposure similar to a daily dose of 600 mg when taken without rifampicin. 
Kod istodobne primjene rifampicina u bolesnika tjelesne težine od 50 kg ili veće, povećanje dnevne doze efavirenza na 800 mg može imati sličnu izloženost kao kod primjene dnevne doze od 600 mg bez rifampicina.
In HIV infected patients at steady-state, mean Cmax, mean Cmin, and mean AUC were linear with 200 mg, 400 mg, and 600 mg daily doses. 
U bolesnika zaraženih HIV-om, srednje vrijednosti Cmax, Cmin i AUC u stanju dinamičke ravnoteže bile su linearne pri dnevnim dozama od 200 mg, 400 mg i 600 mg.
Interaction not studied. 
Nisu provedena ispitivanja interakcija.